L. Mourey

P. Rischmann, L. Balardy, I. Latorzeff, 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.

J. Bachaud, B. Malavaud, L. Bujan, 2004, European urology.

Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.

F. Dalenc, C. Chevreau, V. Sibaud, 2011, Acta dermato-venereologica.

Epoetin alfa and intravenous iron sucrose to treat severe anemia in a patient with chronic radiation enteropathy

R. Bugat, L. Mourey, S. Séronie-Vivien, 2003, Medical oncology.

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.

L. Appleman, G. Gravis, E. Yu, 2022, European urology.

Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy

D. Pouessel, G. Ploussard, L. Mourey, 2020, Expert review of anticancer therapy.

Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy {+/-} docetaxel--An analysis of final safety results.

S. Culine, S. Oudard, P. Beuzeboc, 2010 .

625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update

L. Appleman, G. Gravis, E. Yu, 2020 .

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

L. Appleman, G. Gravis, E. Yu, 2019 .

Routine FDG PET‐CT in patients with a high‐risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases

N. Meyer, S. Zerdoud, C. Chevreau, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors

D. Pouessel, C. Chevreau, F. Puisset, 2020, European Journal of Clinical Pharmacology.

Use of comprehensive geriatric assessment (CGA) to define frailty in geriatric oncology: Searching for the best threshold. Cross-sectional study of 418 old patients with cancer evaluated in the geriatric frailty clinic (G.F.C.) of Toulouse (France).

S. Sourdet, S. Gérard, L. Balardy, 2019, Journal of geriatric oncology.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

A. Ravaud, S. Culine, G. Deplanque, 2015, The Lancet. Oncology.

Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial.

E. Blot, V. Girre, E. Brain, 2011, Critical reviews in oncology/hematology.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

A. Ravaud, J. Machiels, B. Esterni, 2013, The Lancet. Oncology.

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

A. Ravaud, S. Culine, G. Deplanque, 2012, European journal of cancer.

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.

A. Ravaud, S. Culine, G. Le Teuff, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

J. Carles, Choung-Soo Kim, A. Font, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer

D. Pouessel, C. Chevreau, E. Chatelut, 2023, Cancers.

Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol

Y. Rolland, G. Abellán van Kan, T. Filleron, 2019, BMC Cancer.

Digestive Organ Aging and Cancer

G. A. Kan, S. Gérard, L. Balardy, 2020, Geriatric Oncology.

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

D. Bajorin, H. Nishiyama, A. Balar, 2019, Journal of Clinical Oncology.

Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings

R. Motzer, M. Lacouture, C. Estilo, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

B. Escudier, F. Joly, B. Laguerre, 2017, BMC Cancer.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

T. Powles, G. De Velasco, P. Kellokumpu-Lehtinen, 2019, European journal of cancer.

HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.

F. Dalenc, C. Chevreau, J. Delord, 2011, The oncologist.

CO21. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome

F. Dalenc, C. Chevreau, J. Delord, 2011 .

Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma

N. Meyer, C. Paul, L. Lamant, 2018, Dermatology.

A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer.

F. Ichas, F. Joly, N. Houédé, 2014, The oncologist.

Outcomes of comprehensive geriatric assessment and surgical management in head and neck cancers of the elderly: an observational study

P. Grosclaude, S. Vergez, A. Dupret-Bories, 2022, European Archives of Oto-Rhino-Laryngology.

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†

S. Culine, J. Bellmunt, W. Su, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey.

H. Cohen, K. Hoang-Xuan, S. Culine, 2018, European journal of cancer.

Impact of a comprehensive geriatric assessment on decision‐making in older patients with hematological malignancies

L. Ysebaert, S. Sourdet, T. Filleron, 2020, European journal of haematology.

Enzalutamide induced acute generalized exanthematous pustulosis.

J. Mazereeuw-Hautier, N. Meyer, C. Paul, 2016, Journal of dermatological case reports.

Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer

P. Pourquier, F. Joly, N. Houédé, 2017, Cancer Chemotherapy and Pharmacology.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

A. Ravaud, J. Machiels, B. Esterni, 2014, European journal of cancer.

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

P. Pourquier, F. Joly, N. Houédé, 2015, BMC Cancer.

VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients.

A. Ravaud, T. Valentin, T. Filleron, 2021, Journal of geriatric oncology.

Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.

G. Deplanque, S. Oudard, G. Gravis, 2015 .

Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.

S. Culine, G. Gravis, Anne-Laure Martin, 2014 .

Effect of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone on quality of life: Results from a phase III study in non-metastatic high-risk prostate cancer (PC) patients (pts) with a rising PSA status.

S. Culine, S. Oudard, P. Beuzeboc, 2013 .

Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review

F. Dalenc, T. Filleron, J. Boher, 2017, Breast Cancer Research and Treatment.

French general practitioners' sense of isolation in the management of elderly cancer patients.

S. Oustric, L. Balardy, M. Rougé Bugat, 2016, Family practice.

Very long-term complete remission can be achieved in men with high-risk localized prostate cancer and a very high PSA value: an analysis of the GETUG 12 Phase 3 trial

S. Culine, D. Drubay, G. Deplanque, 2023, Clinical Genitourinary Cancer.

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

S. Culine, A. Paci, J. Bay, 2021, Cancer medicine.

Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial.

S. Culine, J. Bay, G. Gravis, 2017 .

Ototoxicity of high-dose carboplatin.

F. Dalenc, C. Chevreau, E. Chatelut, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).

S. Culine, M. Santis, J. Bellmunt, 2014 .

Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial.

D. Bajorin, A. Balar, A. Kamat, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

C. Porta, A. Ravaud, V. Flamand, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.

E. Brain, T. Filleron, J. Boher, 2018, European journal of cancer.

Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).

J. Carles, J. Bono, Choung-Soo Kim, 2016 .

Immune checkpoint inhibitor-related acral vasculitis

O. Beyne-Rauzy, V. Sibaud, P. Cougoul, 2018, Journal of Immunotherapy for Cancer.

Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.

J. Bono, L. Appleman, G. Gravis, 2020 .

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

J. Bono, L. Appleman, G. Gravis, 2020 .

Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40].

T. Powles, G. De Velasco, P. Kellokumpu-Lehtinen, 2019, European journal of cancer.

Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis

C. Porta, A. Ravaud, V. Flamand, 2015 .

No Difference in the Phenotypic Expression of Frailty among Elderly Patients Recently Diagnosed with Cancer vs Cancer Free Patients

Y. Rolland, G. Abellán van Kan, B. Vellas, 2019, The journal of nutrition, health & aging.

Vinflunine Oral Pharmacokinetics and Absolute Bioavailability of Soft and Hard Gelatin Capsules

J. Delord, J. Bennouna, P. Ferré, 2012, Clinical Pharmacokinetics.

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial

O. Trédan, V. D’Hondt, A. Zannetti, 2021 .

Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen

J. Carles, H. Pandha, J. Bono, 2012 .

Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors

D. Pouessel, C. Chevreau, F. Puisset, 2020, European Journal of Clinical Pharmacology.

PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

J. Carles, J. Bono, Choung-Soo Kim, 2016 .

Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.

J. Carles, B. Tombal, F. Calabrò, 2023, Journal of Clinical Oncology.

Perspectives on cancer care in older patients in France

S. Mathoulin-Pélissier, E. Brain, B. Besse, 2020, Ecancermedicalscience.

Tumors: Urologic Cancer

L. Mourey, 2021, Encyclopedia of Gerontology and Population Aging.

KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

J. Bono, L. Appleman, G. Gravis, 2021 .

Taking care of older patients with cancer in the context of COVID-19 pandemic

E. Brain, E. Paillaud, T. Cudennec, 2020, The Lancet Oncology.

Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol

G. Ploussard, B. Cabarrou, L. Mourey, 2023, European Urology Oncology.

PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.

J. Carles, J. Bono, V. Matveev, 2013 .

Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—Results of a planned interim analysis.

G. Gravis, F. Joly, P. Barthélémy, 2020 .

Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.

G. Kramer, S. Byun, M. D. De Santis, 2023, Journal of Clinical Oncology.